Emilia Javorsky
speaker
1,653 appearances
2 recordings
1 series
first heard Mar 2026
last heard 20 Mar
Emilia Javorsky’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Mar 2026 with 2.
Appearances
Recruiting for COVID is just a highly motivated general population.
It's not, I have a rare cancer and there's only a thousand of us on the planet, or I have a disease that I'm going to get in 10 years and don't even know that I have it.
It's a much more difficult thing to potentially recruit for.
Third part of it is that the time between clinical trial enrollment and outcome is very easy when you're in the midst of a pandemic and with an infectious disease, right?
Like in an infectious disease, you're dealing with a time to event that goes between infection and when you are able to detect the virus or your detect symptoms.
And that would for COVID was like five to 10 days.
Right, so within five to 10 days, you pretty much knew like, did this person have the, is this vaccine protective or not?
It's a very quick study to run.
There were even folks that were, and this was something that was totally ethically defensible during the COVID pandemic that wanted to do challenge trials.
which is this idea that like, I'm gonna get infected anyway, being in the population.
Why don't I just go into a clinical study, get the vaccine and then intentionally try and infect me and see whether or not that the vaccine works.
So that compresses it really, again, that idea of like, how do we get...
clinical trial processes down to the biological limits, like that biological limit is in like the five to 10 day area.
Now that is totally different than talking about something like Alzheimer's disease, right?
Where your time to end point, your time to get a result, the time to know if something's working is 10, 11 years, right?
In some of these cases, five to 10 years.
And we see this quite a bit in cancer.
And this is something that's really worth highlighting is a lot of the cancer therapies that we see approved are for late stage cancers.
Now, part of that is because
It's more ethically sort of defensible to experiment in later stage cancers when people have failed treatments, but it's also like cynically easier trial to run because your time to end point, which is does this extend life, is short.
Showing 541–560 of 1,653 · page 28 of 83
← Previous
Next →